Updates are available Erratum dated 2021-06-01
Click to view Erratum: https://doi.org/10.1016/s1470-2045(21)00287-4
-
Authors
Matasar, Matthew J
Capra, Marcelo
Özcan, Muhit
Lv, Fangfang
Li, Wei
Yañez, Eduardo
Sapunarova, Katya
Lin, Tongyu
Jin, Jie
Jurczak, Wojciech
Hamed, Aryan
Wang, Ming-Chung
Baker, Ross
Bondarenko, Igor
Zhang, Qingyuan
Feng, Jifeng
Geissler, Klaus
Lazaroiu, Mihaela
Saydam, Guray
Szomor, Árpád
Bouabdallah, Krimo
Galiulin, Rinat
Uchida, Toshiki
Soler, Lidia Mongay
Cao, Anjun
Hiemeyer, Florian
Mehra, Aruna
Childs, Barrett H
Shi, Yuankai
Zinzani, Pier Luigi
-
Funding
Funding for this research was provided by:
Bayer AG
Bayer Fund
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Journal Title: The Lancet Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1470-2045(21)00145-5
Content Type: article
Copyright: © 2021 Elsevier Ltd. All rights reserved.
